Numerous studies have demonstrated higher levels of blood GFAP in AD patients compared to other neurodegenerative diseases due to variations in neuroinflammation heterogeneity or different types/patterns of astrocyte hyperplasia observed across various neurodegenerative conditions (17). Here, GFAP is linked to neurodegenerative disease.